Company intelligence / Profile preview

Pi Therapeutics

Ness Ziona, Israel

Ownership: Private
Development stage: Other

Overview

Pi Therapeutics was a preclinical-stage oncology company developing small-molecule protein degradation modulators that affect proteostasis pathways to selectively target cancer cells; published information describes compelling preclinical safety and efficacy versus existing protein degradation inhibitors, but no clinical trials were initiated before the company became inactive.[1][2][5]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pi Therapeutics.

Explore the full profile